FibroGen to Report First Quarter 2025 Financial Results
FibroGen (NASDAQ: FGEN) has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025, after market close. The company will host a conference call and webcast presentation at 5:00 PM Eastern Time on the same day, where management will discuss financial performance and provide a business update. The event will include a live Q&A session following the presentation. Interested participants can access the audio webcast through the company's website, and phone dial-in details will be provided upon registration. A replay of the webcast will be available for a limited time on FibroGen's Events & Presentations webpage.
FibroGen (NASDAQ: FGEN) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per lunedì 12 maggio 2025, dopo la chiusura del mercato. La società terrà una conference call e una presentazione in webcast alle 17:00 ora della costa orientale dello stesso giorno, durante le quali la direzione discuterà delle performance finanziarie e fornirà un aggiornamento sul business. L'evento includerà una sessione di domande e risposte in diretta al termine della presentazione. I partecipanti interessati potranno accedere all'audio webcast tramite il sito web dell'azienda, mentre i dettagli per la chiamata telefonica saranno forniti al momento della registrazione. Una replica del webcast sarà disponibile per un periodo limitato nella pagina Eventi e Presentazioni di FibroGen.
FibroGen (NASDAQ: FGEN) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el lunes 12 de mayo de 2025, después del cierre del mercado. La compañía realizará una llamada conferencia y una presentación por webcast a las 5:00 PM hora del Este ese mismo día, donde la dirección discutirá el desempeño financiero y proporcionará una actualización del negocio. El evento incluirá una sesión de preguntas y respuestas en vivo tras la presentación. Los interesados podrán acceder al audio del webcast a través del sitio web de la empresa, y los detalles para la llamada telefónica se proporcionarán al registrarse. Una repetición del webcast estará disponible por tiempo limitado en la página de Eventos y Presentaciones de FibroGen.
FibroGen (NASDAQ: FGEN)은 2025년 1분기 재무 실적 발표를 2025년 5월 12일 월요일 장 마감 후에 예정하고 있습니다. 회사는 같은 날 동부 표준시 오후 5시에 컨퍼런스 콜과 웹캐스트 발표를 진행하며, 경영진이 재무 성과를 논의하고 사업 현황을 업데이트할 예정입니다. 발표 후에는 실시간 질의응답 시간이 포함됩니다. 관심 있는 참가자는 회사 웹사이트를 통해 오디오 웹캐스트에 접속할 수 있으며, 전화 접속 정보는 등록 시 제공됩니다. 웹캐스트 녹화본은 FibroGen의 이벤트 및 프레젠테이션 페이지에서 제한된 기간 동안 시청할 수 있습니다.
FibroGen (NASDAQ : FGEN) a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le lundi 12 mai 2025, après la clôture des marchés. La société organisera une conférence téléphonique et une présentation en webcast à 17h00 heure de l'Est le même jour, au cours desquelles la direction discutera des performances financières et donnera une mise à jour sur les activités. L'événement comprendra une session de questions-réponses en direct à la suite de la présentation. Les participants intéressés pourront accéder au webcast audio via le site web de l'entreprise, et les détails pour la connexion téléphonique seront fournis lors de l'inscription. Une rediffusion du webcast sera disponible pendant une durée limitée sur la page Événements et Présentations de FibroGen.
FibroGen (NASDAQ: FGEN) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Montag, den 12. Mai 2025, nach Börsenschluss, geplant. Das Unternehmen wird am selben Tag um 17:00 Uhr Eastern Time eine Telefonkonferenz und eine Webcast-Präsentation abhalten, bei der das Management die finanzielle Leistung besprechen und ein Geschäftsupdate geben wird. Die Veranstaltung beinhaltet eine Live-Fragerunde nach der Präsentation. Interessierte Teilnehmer können den Audio-Webcast über die Unternehmenswebsite verfolgen, und die Telefon-Einwahldaten werden bei der Anmeldung bereitgestellt. Eine Aufzeichnung des Webcasts wird für begrenzte Zeit auf der Seite Veranstaltungen & Präsentationen von FibroGen verfügbar sein.
- None.
- None.
SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Conference Call and Webcast Presentation
The FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on FibroGen’s website.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.fibrogen.com.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@fibrogen.com
FAQ
When will FibroGen (FGEN) report Q1 2025 earnings?
What time is FibroGen's Q1 2025 earnings call?
How can I access FibroGen's Q1 2025 earnings call?
Will there be a replay available for FibroGen's Q1 2025 earnings call?
